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Muscular dystrophy: The worm turns to genetic disease
Jeffrey S. Chamberlain* and Guy M. Benian†
A new animal model for studying muscular dystrophy, a
mutant form of the nematode Caenorhabditis elegans,
brings the power of worm genetics to bear on the
search for a cure for this disease; work on this worm
has already led to the identification of a novel
component that can suppress the mutant phenotype.
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The human genome project has generated great
expectations for advancing our understanding of genetic
diseases and developing cures. One of the first human
genes identified using genomic technology was the
dystrophin gene, which is defective in Duchenne and
Becker muscular dystrophies [1]. Despite the enormous
amount of information that we have gained about the
function of dystrophin and its tightly associated protein
complex, there is still, sadly, no cure for Duchenne muscular
dystrophy. A number of animal models for Duchenne
muscular dystrophy are available, but there is particular
interest in a new model, a mutant form of the nematode
worm Caenorhabditis elegans, reported by Segalat and col-
leagues [2] in a recent issue of Current Biology. This recent
work raises hope that the fruits of the genome project
might be combined with the power of C. elegans genetics
to accelerate the search for a cure for Duchenne muscular
dystrophy. Analyzing the function of muscle proteins in
mouse and human systems can be slow and difficult, and
the ability to study muscular dystrophy in C. elegans adds a
new dimension to the field.
Genetic analysis in C. elegans is providing important insights
into the assembly and function of muscle (reviewed in
[3,4]). Because muscle structure and muscle proteins are
highly conserved, much of what is learned from the nema-
tode can be extrapolated to other animals, including man.
The worm is a particularly attractive organism in which to
study muscle. The usual self-fertilization allows propaga-
tion of muscle mutants that render animals so uncoordi-
nated that they would be unable to mate. Large numbers
of animals can be handled, thereby making screens for rare
mutations, including extragenic suppressors or enhancers,
practical. Many of the components of the myofibrils and
their membrane–extracellular matrix attachment structures
have been identified, primarily by first identifying
mutants that are slow moving adults — the ‘Unc’ class —
or those that die as embryos with a characteristic pheno-
type — the ‘Pat’ class. 
Until recently, most of what was known about the function
of dystrophin came from studies in mice [5]. Dystrophin,
and the closely related homolog utrophin, are cytoskeletal
proteins that link the subsarcolemmal cytoskeleton to the
extracellular matrix (Figure 1) [6]. The amino-terminal α-
actinin-like domain of dystrophin and portions of the
spectrin-repeat-containing rod domain bind actin, while
the WW domain, the cysteine-rich region and the coiled-
coil-containing carboxy-terminal domain bind a large
complex known as the dystrophin glycoprotein complex.
The dystrophin glycoprotein complex appears to be com-
posed of at least two functionally distinct subcomplexes,
one composed of the proteins dystroglycan, sarcoglycan
and sarcospan, and the other of dystrobrevin and syntrophin.
Several additional proteins bind the dystrophin glycoprotein
complex with lower affinity, including neuronal nitric
oxide synthase (nNOS; Figure 1). As dystroglycan links
dystrophin to the extracellular matrix by binding to
laminin, it has been assumed that the dystrophin glycopro-
tein complex plays a mechanical role in protecting muscle
cells from contraction-induced injury [7]. Nonetheless,
several lines of evidence suggest that the syntrophin–dys-
trobrevin subcomplex may play a signaling, rather than a
mechanical role, and it is possible that the sarcoglycans
play both roles [8–10]. It has, however, proved difficult to
further our understanding of these roles, and of the nature
of the signals that might be transmitted, through experi-
ments using mammalian models.
Interestingly, perusal of the C. elegans genome sequence in
the WormPD database (Proteome, Inc.) reveals genes
encoding homologs of many of the components of the
mammalian dystrophin glycoprotein complex. These
include genes for a homolog of γ-sarcoglycan (F07H5.2)
and two syntrophin homologs (F27D9.8 and F30A10.8),
and single copies of genes encoding proteins very similar to
dystrophin (dys-1) [11] and dystrobrevin (dyb-1) [12]. There
is also a predicted protein, T21B6.1, with weak similarity
to human dystroglycan 1. A recent search for genes encod-
ing homologs of known cytoskeletal proteins in the com-
plete Drosophila genome [13] revealed single copies of
genes coding for homologs of dystrophin (CG7240) and
dystrobrevin (CG8529). Also, as is true of the worm, the fly
apparently has two syntrophins (CG4905 and CG7151).
Thus, as first reported by Roberts and Bobrow [14], inver-
tebrates have a single gene for dystrophin, whereas
humans have three, for dystrophin, utrophin and DRP2. It
is inferred that duplication of the invertebrate dystrophin
gene early in vertebrate evolution gave rise to DRP2 and a
common ancestor of dystrophin and utrophin. Later, a
second duplication of one of these genes resulted in sepa-
rate dystrophin and utrophin genes. As reported by Bessou
et al. [11], the nematode dystrophin homolog has a very
similar domain organization to human dystrophin.
The dystrophin gene in C. elegans was identified by forward
genetics: Bessou et al. [11] isolated multiple loss-of-
function mutations in the same gene, dys-1, that rendered
the worms hyperactive. Subsequent molecular analysis
revealed that dys-1 encodes the only dystrophin homolog
in the worm. The dys-1 mutants are hyperactive, have
exaggerated bending of the anterior part of their bodies,
and have a tendency to hypercontract when moving back-
wards. The authors reasoned that the motility defects
might result from increased cholinergic activity, so they
tested dys-1 mutants for sensitivity to the drug aldicarb,
which blocks acetylcholinesterase and thereby increases
the levels of acetylcholine in the synaptic cleft. They
found that dys-1 mutants are indeed significantly more
sensitive to aldicarb than wild-type animals. They further
confirmed that dys-1 mutants are hypersensitive to acetyl-
choline by measuring muscle membrane depolarization in
response to increasing concentrations of acetylcholine.
Significantly, the muscle structure of dys-1 mutants was
found to be normal, and there was no evidence of
degeneration. Bessou et al. [11] investigated the expres-
sion pattern of dys-1 by linking the gene’s probable regula-
tory sequences to a reporter coding for green fluorescent
protein; the expression of this reporter construct in trans-
genic worms indicated that dys-1 is expressed only in
muscle. Interestingly, these investigators were able to
obtain partial rescue of the hyperactive phenotype of dys-1
mutants by expression of a transgene encoding the very
amino-terminal 358 residues of the nematode protein and
the carboxy-terminal half of the human protein. 
In the conclusion of their paper, Bessou et al. [11] noted
that “in C. elegans, four additional genes lead, when
mutated, to a phenotype similar to that of the dys-1
mutants”. One of these genes, dyb-1, was found by Segalat
and colleagues [12] to encode dystrobrevin. C. elegans dys-
trobrevin is 38% identical in sequence to the human and
mouse dystrobrevin α1 isoforms, and only lacks the
phospho-tyrosine-containing tail that is present in several
mammalian dystrobrevins. Furthermore, although mam-
malian dystrobrevins are specified by two genes encoding
multiple isoforms, C. elegans contains just a single gene
without evidence of alternative splicing. Because dyb-1
and dys-1 mutants have nearly identical behavioral and
pharmacological phenotypes, it was argued that their
protein products have similar physiological functions.
Moreover, the phenotypes suggest that both proteins have
a role in cholinergic signaling. Curiously, this is consistent
with the original identification of dystrobrevin as a protein
that copurified with nicotinic acetylcholine receptors from
Torpedo postsynaptic preparations. In mammals, a special-
ized dystrophin glycoprotein complex, anchored by
utrophin rather than dystrophin, contains specific isoforms
of dystrobrevin and syntrophin and plays a role in acetyl-
choline receptor clustering [15].
Segalat and colleagues [2] have now gone on to construct a
double mutant C. elegans, carrying a combination of a dys-1
null mutation and a weak mutation in hlh-1, which encodes
a homolog of the muscle-specific transcription factor MyoD.
Remarkably, the dys-1(0); hlh-1(weak) animals show a time-
dependent loss of motility and egg-laying, and muscle
degeneration. This is very similar to the observations on
mouse mutants. Mice mutant for just the dystrophin gene
mdx show only a mild myopathy; mice lacking both dys-
trophin and MyoD, however, show a severe myopathy
[16]. Nevertheless, the two types of double mutant are not
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Figure 1
Structure of the mammalian dystrophin glycoprotein complex.
Dystrophin/utrophin (Dys/Utr) is shown as an extended rod that binds
actin and members of the dystrophin glycoprotein complex (most of
the central rod domain is not shown). Dystroglycan (Dg) links to
laminin in the extracellular matrix. In muscle, the dystrophin
glycoprotein complex is located along the sarcolemma, while the
related utrophin complex is located at neuromuscular and
myotendinous junctions. At neuromuscular junctions, the utrophin
complex helps organize large clusters of acetylcholine receptors
(AChR), probably through an interaction with rapsyn (R). Dystroglycan
at the neuromuscular junction can also bind agrin and perlecan. Other
proteins shown are the sarcoglycans (Sg), sarcospan (Sp), syntrophins
(Syn), dystrobrevins (Db), and nitric oxide syntase (NOS). The
syntrophins have been shown to bind many different proteins, including
several protein kinases (see [15] for a review).
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entirely analogous. In mice, the increased severity of the
myoD; mdx phenotype is likely to result from a reduced
ability of muscle to regenerate from ‘satellite’ stem cells.
Nematode muscle, however, does not contain satellite
cells. In C. elegans, muscle forms in the absence of MyoD,
but it does not contract properly. The mild myoD mutation
in this double mutant, by itself, has no obvious effect on
muscle structure or function. It remains a mystery why
muscle degenerates in dys-1; hlh-1 double mutant worms.
Segalat and colleagues [2] hope to use the double mutant
worm to look for suppressors of the muscle degeneration,
not only to identify new components of the dystrophin
glycoprotein complex but also to identify potential targets
for the therapy of Duchenne muscular dystrophy and
Becker muscular dystrophy. As a proof of concept, they
isolated a gene, dyc-1, mutations in which cause a hyperac-
tive phenotype similar to dys-1 and dyb-1. The dyc-1 gene
encodes a novel protein with two regions of homology to
the mammalian nitric oxide synthetase binding protein
CAPON, and is expressed in nematode muscles. More
importantly, the authors found that, when dyc-1 is overex-
pressed, it partially suppresses the degeneration pheno-
type of the dys-1; hlh-1 double mutants, thus proving the
feasibility of future suppressor screens.
These efforts should provide an important complement to
current attempts in man and mouse to understand the
pathophysiological mechanisms that lead to muscular
dystrophy when dystrophin or other members of the
dystrophin glycoprotein complex are defective. Human
homologs of proteins identified in a C. elegans suppressor
screen might be candidates for gene therapy approaches
for Duchenne muscular dystrophy. While numerous labs
are attempting to develop gene replacement therapy for
Duchenne muscular dystrophy, there remain many obsta-
cles [17]. For example, the dystrophin gene and its
protein product are enormous, and difficult to deliver via
viral shuttle vectors. Also, there are concerns that dys-
trophin might elicit an immune response when adminis-
tered to patients, most of whose mutations are nulls. The
direct delivery, or upregulated synthesis, of another gene
product whose overexpression might suppress the dys-
trophic phenotype could prove to be an elegant method of
therapy. Several labs are currently exploring the ability to
upregulate the dystrophin homologue utrophin by admin-
istering small molecules that might regulate utrophin gene
expression [18]. 
Another approach to therapy, spurred by the genome
project, involves a detailed analysis of globally misregu-
lated gene expression in various forms of muscular dystro-
phy. This approach might identify essential members of
pathways that are directly or indirectly affected by misex-
pression of dystrophin. Although this is enormously chal-
lenging, even with microchip technology, the relative
simplicity of C. elegans muscle biology offers a facile method
to streamline such a search. The worm system also offers
the potential for rapid testing of experimental drugs or
genes before embarking on long-term and expensive
experiments in mice and humans. It is perhaps fitting that
study of the largest and arguably most complex gene iso-
lated to date, dystrophin, has finally succumbed to the
power and elegance of the simple worm C. elegans. 
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